

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/55, G01N 33/50</b>		A1	(11) International Publication Number: <b>WO 98/50066</b> (43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: <b>PCT/US98/08838</b>		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 30 April 1998 (30.04.98)		Published <i>With international search report.</i>	
(30) Priority Data: 08/852,395 7 May 1997 (07.05.97) US			
(71) Applicant: TRUSTEES OF TUFTS COLLEGE [US/US]; Ballou Hall, 4th floor, Medford, MA 02155 (US).			
(72) Inventors: HUBER, Brigitte, T.; 175 Grove Street, Cambridge, MA 02111 (US). SCHMITZ, Tracy; 475 Huron Avenue, Cambridge, MA 02138 (US). UNDERWOOD, Robert; 93 Walker Street, Quincy, MA 02171 (US).			
(74) Agent: PLUMER, Elizabeth, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).			
(54) Title: POTENTIATION OF THE IMMUNE RESPONSE THROUGH DELIVERY OF COMPOUNDS BINDING A CYTOPLASMIC DIPEPTIDASE			
(57) Abstract			
<p>A method for stimulating proliferation of T-cells containing cytoplasmic post-prolyl dipeptidase activity; the method, in one aspect, involves contacting the T-cells with an organic compound at a concentration below <math>10^{-8}</math>M, wherein the compound is characterized in that: (a) it is capable of crossing the membrane of T-cells to enter the cytoplasm, (b) it binds to the dipeptidase activity at a concentration of below <math>10^{-8}</math>M, and thus (c) stimulates proliferation of the T-cells at that concentration.</p>			

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## POTENTIATION OF THE IMMUNE RESPONSE THROUGH DELIVERY OF COMPOUNDS BINDING A CYTOPLASMIC DIPEPTIDASE

Government Support

5 This work was funded in part by grant number A136696 from the National Institutes of Health. Accordingly, the United States Government may have certain rights to this invention.

Cross-Reference to Related Applications

This application claims priority from U.S. Patent Application Serial No. 08/852,395, 10 filed on May 7, 1997, entitled POTENTIATION OF THE IMMUNE RESPONSE. The contents of this U.S Patent application are hereby expressly incorporated by reference.

Background of the Invention

This invention relates to treatment of viral infections using organic compounds which 15 interact with T-cell enzymes.

One of the classic markers of full-blown AIDS resulting from long-term infection with HIV-1 is a severe depletion of CD4<sup>+</sup> T-cells, which are a key component of the immune system. Attempts have been made to increase the CD4<sup>+</sup> counts of AIDS patients, and some of these efforts, notably treatment with protease inhibitors, have met with considerable success. 20 Other approaches, e.g., stimulation of the immune response by vaccination with viral peptides, have been less successful. The reasons for CD4<sup>+</sup> depletion in AIDS, and resistance of CD4<sup>+</sup> cells to stimulation by some therapies, are not fully understood.

Summary of the Invention

We have discovered that the activation state of human T-cells can be affected by 25 compounds which interact with a cytoplasmic post-prolyl dipeptidase activity which has similarities to, but is distinct from , the membrane-bound T-cell serine protease CD26. The compounds useful in the invention are inhibitors of this activity, which is, in naturally- occurring T-cells in healthy individuals, involved in protection of T-cells from apoptosis, or 30 programmed cell death. Thus, in high concentrations, the inhibitors hasten the death of T-cells, by inhibiting the protective enzyme. We have discovered, surprisingly, that at low concentrations the inhibitors exhibit a paradoxical effect: they are potent stimulators of T-cell activity in HIV-infected individuals. The concentrations of inhibitor which induce this T-cell

stimulatory response are very low (on the order of  $10^{-8}$ - $10^{-12}$ M), and therefore the inhibitors can be used with minimal side effects, even if, in larger doses, the inhibitors would be toxic.

Our hypothesis is that the resistance to full activation observed in T-cells of HIV-infected individuals involves a blocking of the cytoplasmic enzymatic activity discussed above.

- 5 We believe that this blocking of activation, involving this cytoplasmic activity, prevents differentiation of T-cells of HIV-infected individuals into effector cells, eventually leading to T-cell death.

Thus, the invention features a method for stimulating proliferation of T-cells of a human patient suffering from a disease state characterized by the inability of the patients' T-cells to  
10 respond normally to T-cell proliferation-inducing stimuli; the method involves contacting the T-cells with an organic compound at a concentration below  $10^{-8}$ M, wherein the compound is characterized in that it binds to the post-prolyl cleaving dipeptidase activity present in the cytoplasm of human T-cells, e.g., CD4<sup>+</sup> cells or Jurkat cells.

Treatment according to the invention can be *in vitro* or *in vivo*. In *in vivo* therapy, the  
15 enzyme-interacting compound of the invention is administered such that the blood concentration in the patient (e.g., an HIV-infected patient) is below  $10^{-11}$ . The compounds can also be used *in vitro* at low concentrations to stimulate proliferation of non-infected, beneficial T-cells, such as CD4<sup>+</sup> cells and CTL's. In this embodiment, PBMC are isolated from a patient and incubated with a concentration of lower than  $10^{-8}$ M of the compound, to bring about  
20 proliferation of T-cells, which are then reinfused into the patient.

We believe that administration of low concentrations of the inhibitors of the invention may have an allosteric effect such that the T-cell cytoplasmic enzyme, which is a multimeric (i.e., multiple subunit) enzyme, exhibits an increased affinity of the enzyme for its natural substrate or ligands, allowing the previously blocked T-cell to proceed to full activation, and  
25 hence survival, proliferation, and interleukin-2 production. Stimulation of the T-cell immune response in HIV-infected patients according to the invention yields increased numbers of immune effector cells, which can fight both HIV itself, and other opportunistic pathogens.

Treatment according to the invention has the advantages of specificity and low toxicity, not just because of the low concentrations of inhibitor which can be used, but also because, in  
30 T-cells of patients not infected with a virus such as HIV, the inhibitors have no discernable effect. Furthermore, treatment according to the invention advantageously does not necessarily require *in vitro* manipulation of the T-cells from HIV-infected patients. Furthermore, no

immunization is required, and treatment will be effective even where HIV proteins have mutated because the therapy targets a cellular enzyme. The fact that, in T-cells treated according to the invention *in vitro*, no increase in the level of the HIV protein p24 is observed, probably indicates that the T-cells which are infected with HIV are not stimulated by the low  
5 dose inhibitor treatment of the invention.

The invention also permits immunization of HIV-infected patients with, e.g., HIV peptides. Under normal circumstances, such patients cannot be vaccinated because of the defect in the T-cell stimulation pathway. Use of inhibitors in low doses as adjuvants can render T-cells responsive to vaccination with HIV antigens, in particular peptides.

10 Treatment of HIV-infected patients with low doses of inhibitors according to the invention can also enhance the activity of other AIDS drugs, in particular protease inhibitors. We have found that treatment according to the invention generally fails to bring about an increase in CD4<sup>+</sup> count in patients whose CD4<sup>+</sup> count is already very low, i.e., below about 15 400. In such patients, the CD4<sup>+</sup> count can be increased to above this level using known protease inhibitors, and the newly generated CD4<sup>+</sup> T-cells resulting from such treatment are particularly susceptible to the stimulatory effects of treatment according to the invention, leading to an optimal combination of AIDS therapy. Preferably, the drugs are administered orally.

20 The low dose administration of inhibitors of the invention can also be used to produce an adjuvant effect in HIV-negative individuals, who are to be immunized with peptides or other viral antigens; this mode of vaccination can be used for prophylaxis for HIV, as well as any other viral pathogen. Ordinarily, meaningful cytolytic T-lymphocyte ("CTL") responses, both *in vitro* and *in vivo*, have been difficult to achieve with peptide immunization. The invention should make it possible to produce significant CTL responses to viral peptides, e.g., peptides  
25 from influenza, HIV, human papilloma virus, and herpes viruses. This adjuvant effect can also be used to stimulate CTL responses to peptide antigens from other pathogens as well, e.g., pathogenic bacteria such as toxigenic *E. coli*, and protozoan pathogens such as the pathogens which are the causative agents of malaria and amoebic dysentery. The compounds, when used as adjuvants, are preferably administered orally.

30 The invention provides a new and highly advantageous method of potentiating the immune response in both HIV infected and uninfected patients, in methods employing extremely low concentrations of inhibitors which, at these concentrations, exhibit a paradoxical

effect (i.e., they act as stimulatory rather than inhibitory molecules, as they would at higher concentrations). The very low concentrations employed according to the invention allows treatment with minimal side reactions and toxicity. The specificity of the treatment of the invention also avoids such adverse effects, which are seen, for example, in treatment with  
5 immune stimulatory compounds such as interleukin-2.

Other features and advantages of the invention will be apparent from the following detailed description thereof, and from the claims.

#### Brief Description of the Drawings

10 Fig. 1 is a pair of graphs showing the lymphocyte stimulatory effect of treatment of the invention on peripheral blood mononuclear cells (PBMC) from HIV-infected and uninfected patients. Fig. 1A shows the effect of the compound on T-cell proliferation *in vitro* for PBMC from an HIV-1<sup>+</sup> individual and Fig. 1B shows the effect of the compound on T-cell proliferation *in vitro* on PBMC from an HIV-1<sup>-</sup> individual. Each of Figs. 1A and 1B illustrate a  
15 representative experiment out of a total of ten experiments.

Fig. 2 is a graph illustrating the T-cell stimulatory effects of two inhibitory compounds used according to the invention (date of experiment: 3/9/95; patient id no:1655185; CD4 antibody count:760; and number of cells/well: 0.4 x 10<sup>6</sup>).

20 Fig. 3 is a graph showing the stimulatory effect of treatment according to the invention in lymphocytes of HIV-infected patients, compared to treatment using two control compounds (date of experiment: 3/15/95; patient id no: 1227604; CD4 antibody count: 230; number of cells/well: 0.16 x 10<sup>6</sup> ; and ½ area of a 96 well plate).

25 Fig. 4 is a graph showing the stimulatory effect of treatment according to the invention in lymphocytes of HIV-infected patients, compared to treatment using two control compounds (date of experiment 3/23/95; patient id no. 1586496; CD4 antibody count: 830; number of cells/well: 0.4 x 10<sup>6</sup> ).

30 Fig. 5 is a graph illustrating a stimulatory effect of an inhibitor according to the invention on PBMC *in vitro*, showing the correlation with CD4<sup>+</sup> counts. The data are plotted as the natural log of the stimulation index (vertical dimension) versus the natural log of the CD4<sup>+</sup> count of the patient (horizontal dimension)(71 patients total; P=<0.0001; RR=2.04 (1.5-2.9)).

Fig. 6 is a histogram demonstrating that an inhibitor according to the invention induces dose-dependent apoptosis in resting T-cells (these dosages are higher than the extremely low

doses used according to the invention). CD19+B cells and CD4+/CD8+Tcells were isolated (>90% and >97% purity, respectively). The cells were then incubated overnight in the presence or absence of VBBP ( $10^{-4}$  M or  $10^{-6}$  M). The amount of death induced by VPB treatment was determined by 7AAD flow cytometry analysis. The data represents the mean percentage of  
5 death from duplicate samples.

Fig. 7 is a histogram demonstrating that an inhibitor according to the invention induces, at higher doses than in the invention, dose-dependent apoptosis in both CD26<sup>+</sup> and CD26<sup>-</sup> populations of PBMC. The CD26<sup>+</sup> and CD26<sup>-</sup> PBMC populations were found to be equally susceptible to DPPIV inhibitor induced death. PBMC were stained with the anti-CD26  
10 monoclonal antibody, 4 EL, and then sorted into CD26<sup>+</sup> and CD26<sup>-</sup> populations using a facstar plus dual lasar flow cytometry. The cells expressing the highest level (5%) of CD26 and the cells expressing the lowest level (bottom 10%) of CD26 were isolated as the CD26<sup>+</sup> and CD26<sup>-</sup> populations respectively. The purity of the populations as examined by staining with the anti-CD26 monoclonal antibody, 134-2C2, is >90%. The CD26<sup>+</sup> and CD26<sup>-</sup> populations were  
15 cultured overnight in the presence or absence of various concentrations of VBP. The amount of death induced by VBP treatment was determined by 7AAD flow cytometry analysis. Data represent mean of death from duplicate samples +/- SD.

Fig. 8 is a graph showing that an inhibitor of CD26 (val-boroPro) inhibited the cytoplasmic enzyme as well.

20 Fig. 9 is a graph showing the stimulatory effect of treatment according to the invention in lymphocytes of HIV-infected patients, compared to treatment using two control compounds. Fluoroolefins did not induce cell death. PBMC were cultured overnight in the presence or absence of DPPIV inhibitors, L125, a fluorooolefin containing Npeptidal Oacil hydroxyl amine inhibitor or VBP. The amount of death induced was determined by 7AAD flow cytometry  
25 analysis. The data represents the mean percent death from duplicate samples.

#### Detailed Description

##### Therapeutic Compounds

Any organic compound can be used according to the invention which exhibits the following properties: (1) it is capable of crossing the membrane of human T-cells to reach the  
30 cytoplasm, where the compound can (2) interact with the cytoplasmic dipeptidase present in the T-cells, in order to (3) stimulate activation/proliferation of T-cells (and most preferably CD4<sup>+</sup> cells or CTLs) at concentrations below  $10^{-8}$ M.

A simple screening method is described below for the identification of compounds which are candidate therapeutic compounds according to the invention.

### Substrate and Enzyme Preparation

5       The first step is to provide a cytoplasmic enzyme preparation. The preparation need not be a pure enzyme sample; a crude cytoplasmic extract is sufficient to screen compounds for the desired activity. The extract can be prepared from any human T-cell line which is negative for CD26; an example of such a suitable cell line is the commercially available Jurkat cell line.

10      A suitable enzyme-containing cell extract can be prepared as follows. First, Jurkat cells (10<sup>6</sup>-10<sup>11</sup> cells) are grown and a cell pellet is obtained by centrifugation. The cell pellet is stored in frozen condition.

15      For use in the assay, the frozen pellet is thawed by the addition of ice cold lysis buffer, in the amount of approximately 1 ml per 10<sup>8</sup> cells. The liquefied material is homogenized with ten strokes of a Dounce homogenizer, and then clarified by centrifugation at 1500 g. The supernatant is removed (and saved), and the 1500 g pellet is resuspended in lysis buffer and homogenized with ten strokes of a Dounce homogenizer. Clarification is again carried out by centrifugation at 1500 g, 4°C.

20      The 1500 g supernatants are then combined, and EDTA is added to 5 mM. The resultant liquid is centrifuged at 75,000 g at 4°C for twenty minutes, and the supernatant is then removed and centrifuged at 175,000 g at 4°C for 60 minutes. The resultant supernatant, containing the cytosolic extract, is the DPPV activity-containing preparation used in the assay, described below, for candidate therapeutic compounds of the invention.

25      The assay is based on our observation that the T-cell cytoplasmic enzyme of interest is a post-prolyl cleaving serine protease. We therefore chose as a reporter substrate a compound which contains proline in the penultimate position; any of a number of substrates meeting this requirement can be used. In the assay described herein, we employed a fluorescent cleavage assay using the substrate Ala-ProAFC. Alternatively, a colorimetric assay can be carried out using as a substrate Gly-Pro-pNA. The choice of terminal amino acid is not critical, provided that the substrate contain a free terminal amino group.

30      In the assay we carried out, we employed a fluorescence spectrometer for excitation at 400 nm and emission at 505 nm. The spectrometer was calibrated for fluorescence intensity of 0.000= 10 mM HEPES, pH 7.4; and fluorescence intensity of 1.000= 10mM HEPES, 1 μM

AFC.

To carry out the assay, between 10 and 100  $\mu$ l of enzyme extract, above, is diluted to 1 ml with 10mM HEPES, pH 7.4, containing 10mM Ala-ProAFC. At least one extract/substrate sample is run without test compound, to provide a standard for comparison with the test  
5 sample.

In the test samples, multiple samples are run containing varying concentrations, down to  $10^{-8}$ M, of the test compound. The sample (with or without test compound) is placed in a cuvette, and inserted into a fluorescent spectrometer. Enzymatic activity is measured as the accumulation of fluorescence intensity (i.e., substrate cleavage product) over time (1 min.). A  
10 compound is identified as an inhibitor if the accumulative fluorescence is decreased as a result of the presence of the inhibiting compound.  
15

Once a compound has been identified as an enzymatic inhibitor, as described above, further assays are carried out to determine whether the compound is capable of moving across the T-cell membrane into the cytoplasm; this is an assay which can be carried out using well-known techniques.  
15

If desired, additional *in vitro* assays can be carried out using candidate compounds of the invention, prior to their use *in vivo*. One such assay employs the candidate compound at a very low concentration, in a test designed to determine whether at low concentrations the compound can stimulate the proliferation of PBMC from HIV-infected patients *in vitro*. As is  
20 shown in the data of Fig. 4, stimulation can be measured by, e.g., incorporation of a labeled nucleotide.


The compounds can also be tested at higher doses to determine whether they exhibit the opposite effect of proliferation, as above, i.e., dose-dependent apoptosis caused by enzyme inhibition, as in the experiments of Fig. 6.  
25

### **Candidate Compounds**

As is discussed above, compounds which are potentially capable of apoptosis induction at high doses and proliferation induction at low doses are those which, at normal or high doses, inhibit cytoplasmic T-cell dipeptidase, and can cross the T-cell membrane into the T-cell  
30 cytoplasm, where the enzyme interaction occurs. The compounds thus should be organic compounds which have a free amino group at the amino terminus; a proline or proline analog at the penultimate position; and an enzyme binding site which mimics the post-prolyl cleavage

site of cytoplasmic dipeptidase.

A number of known classes of compounds can be screened and used according to the invention. One such class are CD26 (i.e., DPPIV) inhibitors, including those described in Bachovchin et al., U.S. Patent No. 4,935,493, hereby incorporated by reference. In the '493 5 patent, there are described compounds having the structure:



where each D<sub>1</sub> and D<sub>2</sub>, independently, is a hydroxyl group or a group which is capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH; and X comprises an 10 amino acid or a peptide which mimics the site of the substrate recognized by a post-prolyl cleaving enzyme.

The compounds in the '493 patent are inhibitors of CD26, and are also candidate inhibitors of the invention. As is discussed above, because of the low concentrations of compounds used according to the invention, it is acceptable to use, in the invention, a 15 compound which interacts not only with the cytoplasmic enzyme, but also CD26.

The class of compounds described in the '493 patent are also discussed and exemplified in Takacs et al., U.S. Patent Application Serial No. 07/923,337, corresponding to PCT Application No. WO94/03055, hereby incorporated by reference. In this application, one of the families of molecules in the '493 patent is described as the "Xaa-boroPro molecules," 20 exemplified by Ala-boroPro, Pro-boroPro, and Gly-boroPro. These Xaa-boroPro molecules are all candidate compounds for use in the methods of the present invention. Two of these compounds are used in some of the examples described below; those compounds are Lys-boroPro ("KPB") and Val-boroPro ("VBP").

25

### EXAMPLE 1

Peripheral blood mononuclear cells (PBMC) were obtained by standard methods from HIV-infected individuals, and from uninfected individuals. Varying dosages of KPB or VBP were contacted with the PBMC *in vitro*, and stimulation of proliferation was measured by

incorporation of  $^3\text{H}$  thymidine (cpm). The results of these experiments are shown in Fig. 1: very low doses of the Val-boroPro and Lys-boroPro stimulated proliferation of PBMC from HIV-infected patients, but not PBMC from uninfected patients.

As shown in Fig. 1, at no concentration of the boroPro enzyme inhibitor did it affect the 5 PBMC from uninfected individuals. The inhibitor, at moderate concentrations, also did not cause proliferation of PBMC from HIV-infected individuals, but it did cause marked proliferation at very low concentrations ( $10^{-9}$  and  $10^{-10}\text{M}$ ). These results are consistent with our hypothesis, discussed above, that, at low concentrations, these enzyme inhibitors exhibit a paradoxical effect: rather than inhibiting the apoptosis-controlling cytoplasmic T-cell enzyme, 10 they interact with that enzyme in a manner which blocks inactivation and causes proliferation of T-cells.

Concordant results are shown in Fig. 2, a histogram showing that low doses of Lys-boroPro and Val-boroPro cause proliferation of PBMC of HIV-infected patients, while higher doses ( $10^{-4}\text{M}$ ) do not have this effect.

15 The same results are shown in Figs. 3, 4, 9, and 10 which also present data for two control compounds OKT3, and PHA, both of which are non-specific mitogens.

Referring to Fig. 5, data are presented in a form which shows that low concentrations of the inhibitors of the invention have little effect on the PBMC of HIV-infected patients whose CD4 $^{+}$  counts are lower than about 400 (the clinical indication for AIDS). In the graph of Fig. 5, 20 the natural log of the stimulation index (the vertical axis) is plotted against the natural log of the CD4 $^{+}$  count of the patients; as shown, above a count of 400 there is particularly significant stimulation of proliferation.

Fig. 6 is a graph demonstrating that purified T-cells are highly sensitive to cytoplasmic T-cell dipeptidase inhibitors in moderate concentrations. CD19 $^{+}$ B cells and CD4 $^{+}$ /CD8 $^{+}$  T-cells 25 were isolated to high purity and incubated overnight in Val-boroPro. The amount of cell death was determined by 7AAD flow cytometry analysis. Data represent % of cell death from duplicate samples. These data are consistent with our hypothesis that the inhibitors, in moderate concentration, inhibit a cytoplasmic enzyme which ordinarily protects against apoptosis.

30 Fig. 7 presents data demonstrating that CD26 $^{+}$  and CD26 $^{-}$  PBMC are equally susceptible to T-cell cytoplasmic enzyme inhibitor-induced death, where the inhibitor is administered immoderate concentrations. CD26 $^{+}$  and CD26 $^{-}$  populations were incubated

overnight in the presence or absence of various concentrations of Val-boroPro. The amount of cell death was determined by 7AAD flow cytometry analysis. Data represent mean % of death from duplicate samples. These data indicate that apoptosis-inhibiting T-cell cytoplasmic enzyme is present in both CD26<sup>+</sup> and CD26<sup>-</sup> T-cells.

5 Fig. 8 presents data showing the effects of an inhibitor useful in the invention, Val-boroPro. The experiments were carried out using two preparations: purified DPPIV (i.e., CD26), and Jurkat T-cell cytoplasmic extract, described above (Jurkat cells contain the cytoplasmic T-cell enzyme, but do not bear CD26 on their surfaces). These preparations were incubated with varying concentrations of Val-boroPro, and enzymatic activity was determined  
10 10 by measuring the accumulation of the fluorescent cleavage product of 7-amino-4-trifluoromethylcoumarin (AFC) released from the substrate Ala-ProAFC upon enzymatic cleavage. Val-boroPro inhibited both the enzyme DPPIV and the cytoplasmic T-cell enzyme in the Jurkat preparation.

Other embodiments are within the following claims.

15 What is claimed is:

CLAIMS

1. A method for stimulating proliferation of T-cells of a human patient suffering from a disease state characterized by the inability of said patient's T-cells to respond normally to T-cell proliferation-inducing stimuli; said method comprising contacting said T-cells, *in vitro* or *in vivo*, with an organic compound at an *in vitro* concentration below  $10^{-8}$ M, or an *in vivo* blood concentration below  $10^{-8}$ M, wherein said compound is characterized in that it binds to the post-prolyl cleaving dipeptidase activity present in the cytoplasm of Jurkat cells.  
5
2. The method of claim 1, wherein said disease state is caused by HIV infection.  
10
3. The method of claim 1, wherein said compound is further characterized in that, at a concentration of  $10^{-4}$ M, it inhibits the cytoplasmic post-prolyl cleaving dipeptidase activity found in Jurkat T-cells.  
15
4. The method of claim 3, wherein said compound is further characterized in that, at a concentration of  $10^{-8}$ M, it binds to the cytoplasmic post-prolyl cleaving dipeptidase activity of CD4<sup>+</sup> T-cells of HIV-infected patients, to stimulate proliferation of said cells.  
20
5. The method of claim 1, wherein said patient is infected with HIV, and said compound is administered to said patient to bring about a blood concentration of said compound below  $10^{-10}$ M.  
25
6. The method of claim 5, wherein said compound is further characterized in that it is capable of crossing the membrane of human CD4<sup>+</sup> T-cells to enter the cytoplasm.  
30
7. A method for stimulating proliferation of T-cells which contain cytoplasmic post-prolyl cleaving dipeptidase activity and which are further characterized by the inability to respond normally to T-cell proliferation-inducing stimuli, said method comprising contacting said T-cells with an organic compound at a concentration below  $10^{-8}$ M, wherein said compound is characterized in that:
  - (a) it is capable of crossing the membrane of said T-cells to enter the cytoplasm;
  - (b) it binds to said dipeptidase activity at a concentration below  $10^{-8}$ M, and thus,

(c) stimulates proliferation of said T-cells at said concentration.

8. The method of claim 7, wherein said T-cells are CD4<sup>+</sup> cells.

5 9. The method of claim 8, wherein said compound enhances the ability of said CD4<sup>+</sup> T-cells to proliferate in response to antigenic stimulation.

10. The method of claim 1, wherein said compound is a serine protease inhibitor.

10 11. The method of claim 1, wherein said compound is administered to an HIV-infected patient.

12. The method of claim 10, wherein said serine protease inhibitor has a cleavage site or a binding site which mimics a post-proline serine protease cleavage site.

15

13. A method for testing a compound for enzyme inhibitory activity, said method comprising the steps of:

(a) providing a post-prolyl cleaving dipeptidase activity-containing cytoplasmic extract from T-cells which lack CD26 on their surfaces;

20 (b) contacting said extract with a serine protease reporter substrate of said dipeptidase activity, and with said compound; and

(c) determining whether said compound inhibits cleavage of said reporter substrate.

14. A method of treating a patient infected with HIV, said method comprising 25 administering to said patient an organic compound characterized in that:

(a) it inhibits T-cell cytoplasmic post-prolyl cleaving dipeptidase activity at a concentration above 10<sup>-3</sup>M;

(b) it interacts with said dipeptidase activity at a concentration below 10<sup>-8</sup>M, enhancing the ability of said activity to inhibit apoptosis of T-cells of said patient; and

30 (c) it is capable of crossing the membrane of T-cells of said patient to enter the cytoplasm,

wherein said compound is administered to said patient so that its concentration in the

blood of said patient does not exceed  $10^{-8}$ M.

15. The method of claim 14, wherein the CD4<sup>+</sup> count of said patient is higher than 400.

5

16. The method of claim 14, wherein said compound is administered in conjunction with a therapeutic agent which increases the CD4<sup>+</sup> count of HIV-infected patients.

17. A method of treating a viral infection in a patient, said method comprising 10 administering to said patient a viral antigen, together with an adjuvant-acting amount of a compound characterized in that:

(a) it inhibits T-cell cytoplasmic post-prolyl dipeptidase activity at a concentration of about  $10^{-5}$ M;

15 (b) it interacts with said dipeptidase activity at a concentration below  $10^{-8}$ M, enhancing the ability of said activity to inhibit apoptosis of T-cells of said patient; and

(c) it is capable of crossing the membrane of T-cells of said patient to enter the T-cell cytoplasm,

wherein said compound is administered so that its concentration in the blood of said patient does not exceed  $10^{-8}$ M.

20

18. The method of claim 11, wherein said virus is HIV.

19. The method of claim 17, wherein said compound is administered orally.

1/7




FIG. IA




FIG. IB

2/7




FIG. 2

3 / 7




FIG. 3

4 / 7




FIG. 4




FIG. 5




FIG. 6




FIG. 7

7/7




FIG. 8




FIG. 9

# INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 98/08838

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 6 A61K38/55 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 03055 A (US HEALTH ;UNIV TUFTS (US)) 17 February 1994 see page 4, line 9 - page 6, line 27 see page 8 - page 9; example 4 --- WO 91 17767 A (NEW ENGLAND MEDICAL CENTER INC ;UNIV TUFTS (US)) 28 November 1991 see page 1, line 16 - page 3, line 11 --- -/-	1-19
A		1-19

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 August 1998

Date of mailing of the international search report

13/08/1998

Name and mailing address of the ISA  
 European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

## INTERNATIONAL SEARCH REPORT

In .tional Application No

PCT/US 98/08838

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FLENTKE ET AL: "INHIBITION OF DIPEPTIDYL AMINOPEPTIDASE IV (DP-IV) BY XAA-BOROPRO DIPEPTIDES AND USE OF THESE INHIBITORS TO EXAMINE THE ROLE OF DP-IV IN T-CELL FUNCTION" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 88, 1991, pages 1556-1559, XP000578025 see page 1556 see abstract -----	1-19

## INTERNATIONAL SEARCH REPORT

...nternational application No.

PCT/US 98/08838

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim(s) 1-4,7-10,12 partially and 5,6,11,14-19 completely is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2.  Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3.  Claims Nos.:

because they're dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/US 98/08838

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9403055 A	17-02-1994	AU 4794393 A	03-03-1994
WO 9117767 A	28-11-1991	NONE	